Copyright: ©Author(s) 2026.
World J Nephrol. Jun 25, 2026; 15(2): 118877
Published online Jun 25, 2026. doi: 10.5527/wjn.v15.i2.118877
Published online Jun 25, 2026. doi: 10.5527/wjn.v15.i2.118877
Table 4 Kidney function tests in patients with and without diabetes mellitus and control groups, mean ± SD
| Variables | MASLD with DM (n = 50) | MASLD without DM (n = 50) | Control group (n = 50) | P value |
| Urea (mg/dL) | 21.19 ± 8.97 | 16.19 ± 3.11 | 10.24 ± 3.49 | < 0.001 |
| Creatinine (mg/dL) | 1.75 ± 0.60 | 1.35 ± 0.76 | 0.79 ± 0.13 | < 0.001 |
| eGFR (mL/minute) | 79.09 ± 7.98 | 85.98 ± 8.70 | 101.76 ± 2.34 | < 0.001 |
| Albuminuria (mg/day) | 78.17 ± 12.87 | 34.19 ± 5.55 | 12.90 ± 4.12 | < 0.001 |
- Citation: Azoz NM, Shehata MA, Abbas WA, Gadelkareem RA, Abdel Aziz EM. Is the metabolic dysfunction-associated steatotic liver disease a predictor of chronic kidney disease? World J Nephrol 2026; 15(2): 118877
- URL: https://www.wjgnet.com/2220-6124/full/v15/i2/118877.htm
- DOI: https://dx.doi.org/10.5527/wjn.v15.i2.118877